Skip to main content
Clinical Trials/NCT06037941
NCT06037941
Recruiting
Not Applicable

Breathprinting (E-Nose) Technology to Measure Response to Treatment of Malignant Pleural Mesothelioma (MPM) Through MPM-Specific Volatile Organic Compounds Detected in Exhalates

Memorial Sloan Kettering Cancer Center7 sites in 1 country20 target enrollmentSeptember 8, 2023

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Malignant Pleural Mesothelioma
Sponsor
Memorial Sloan Kettering Cancer Center
Enrollment
20
Locations
7
Primary Endpoint
Change of MPMspecific VOCs
Status
Recruiting
Last Updated
7 months ago

Overview

Brief Summary

The researchers are doing this study to test the ability of a new technology called breathprinting, or electronic nose (E-Nose), to measure how people respond to standard treatment for malignant pleural mesothelioma (MPM). The researchers will study how E-Nose breathprints change over time as people receive standard treatment for MPM. They will also look at how changes in people's E-Nose breathprints compare to changes in their standard imaging scans and in biomarkers of MPM in their blood.

Registry
clinicaltrials.gov
Start Date
September 8, 2023
End Date
September 1, 2026
Last Updated
7 months ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Aged 30-85 years
  • No history of thoracic cancer or extrathoracic cancer potentially involving pleural metastases (i.e., breast, gastric, colon, or pancreas cancer)
  • Recent diagnosis of MPM
  • Documented, signed, and dated informed consent, obtained before any procedures, for the proposed research study, and signed standard surgical consent for surgical resection

Exclusion Criteria

  • Aged \<30 or \>85 years at the first outpatient visit
  • History of thoracic or extrathoracic cancer that puts the subject at risk for pleural or pulmonary metastases

Outcomes

Primary Outcomes

Change of MPMspecific VOCs

Time Frame: up to 1 year

compared with imaging (using RECIST 1.1 and mRECIST).

Study Sites (7)

Loading locations...

Similar Trials